Article
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 1 Jan 2023
Tsai Mao-Song, Sun Hsin-Yun, Chen Cheng-Pin, Lee Chen-Hsiang, Lee Chun-Yuan, Liu Chun-Eng, Tang Hung-Jen, Hung Tung-Che, Li Chia-Wen, Lee Yuan-Ti, Liou Bo-Huang, Yang Chia-Jui, Hung Chien-Ching
Abstract excerpt
OBJECTIVES: Real-world experience with coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is sparse as a switch regimen among people living with HIV (PLWH) having achieved viral suppression after previous virologic failures with the emergence of K65N/R. METHODS: In this retrospective study, PLWH aged ≥20 years who had previous virologic failures with emergent K65N/R were included for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.